Table 2.
Use of oral anticoagulant and antiplatelet agents, and other cardiovascular medications in AF patients with and without coronary artery disease.
|
| |||
|---|---|---|---|
| MEDICATIONS | AF AND CAD N = 216 (10.7%) | AF AND NO CAD N = 1804 (89.3%) | P-VALUE |
|
| |||
| Oral anticoagulant agents, N (%) | |||
|
| |||
| - All OACs | 181 (83.8) | 1496 (82.9) | 0.81 |
|
| |||
| - VKA | 56 (25.9) | 606 (33.6) | 0.03 |
|
| |||
| - DOACs | 125 (57.9) | 890 (49.3) | 0.02 |
|
| |||
| Oral antiplatelet agents, N (%) | |||
|
| |||
| Single agent | 120 (55.6) | 670 (37.1) | <0.0001 |
|
| |||
| Dual agents | 39 (18.1) | 85 (4.7) | |
|
| |||
| Single or dual agents | 159 (73.6) | 755 (41.9) | |
|
| |||
| OACs and antiplatelet combination, N (%) | |||
|
| |||
| OAC and one or two antiplatelet agents | 121 (56.0) | 527 (29.2) | <0.0001 |
|
| |||
| Oral antiarrhythmic agents and other medications, N (%) | |||
|
| |||
| Amiodarone | 41 (19.0) | 346 (19.2) | 0.98 |
|
| |||
| Class I antiarrhythmic medications | 2 (0.9) | 35 (1.9) | 0.44 |
|
| |||
| Beta blockers | 185 (85.6) | 1434 (79.5) | 0.04 |
|
| |||
| Digitalis | 20 (9.3) | 299 (16.6) | 0.007 |
|
| |||
| Non-dihydropyridine CCB | 13 (6.0) | 206 (11.4) | 0.02 |
|
| |||
| RAS inhibitors | 106 (49.1) | 675 (37.4) | 0.001 |
|
| |||
| Statins | 149 (69.0) | 603 (33.4) | <0.0001 |
|
| |||
AF: atrial fibrillation; CAD: coronary artery disease; CCB: calcium channel blocker; DOACs: direct oral anticoagulant agents, OACs: oral anticoagulant agents; RAS: renin angiotensin system; VKA: vitamin K antagonists.